China Pharma Holding Inc. CPHI
China Pharma Holding Inc. (NYSE: CPHI) is a specialty pharmaceutical company. Its next catalyst on record is CMO project registration: NMPA regulatory review completion (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CMO project registration — NMPA regulatory review completion (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Candesartan Cilexetil tablets | hypertension | small molecule | Approved |
| Gastrodin Injection | CNS/cerebrovascular | small molecule | Approved |
| Roxithromycin Dispersible Tablets | respiratory/anti-infection | small molecule | Approved |
| Cefaclor Dispersible Tablets | respiratory/anti-infection | small molecule | Approved |
| Compound Ammonium Glycyrrhetate S for Injection | digestive diseases | small molecule | Approved |
| Vitamin B6 for Injection | other | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.